JP7148994B2 - ビスホスホシンゲル製剤及びその使用 - Google Patents

ビスホスホシンゲル製剤及びその使用 Download PDF

Info

Publication number
JP7148994B2
JP7148994B2 JP2019567981A JP2019567981A JP7148994B2 JP 7148994 B2 JP7148994 B2 JP 7148994B2 JP 2019567981 A JP2019567981 A JP 2019567981A JP 2019567981 A JP2019567981 A JP 2019567981A JP 7148994 B2 JP7148994 B2 JP 7148994B2
Authority
JP
Japan
Prior art keywords
formulation
alcohol
patient
weight
gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019567981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020523322A (ja
JP2020523322A5 (https=
Inventor
ケイツ、スティーブン、エイ．
アーサー ジョンソン、キース
Original Assignee
レイクウッド アメディックス、インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by レイクウッド アメディックス、インコーポレイテッド filed Critical レイクウッド アメディックス、インコーポレイテッド
Publication of JP2020523322A publication Critical patent/JP2020523322A/ja
Publication of JP2020523322A5 publication Critical patent/JP2020523322A5/ja
Priority to JP2022147051A priority Critical patent/JP7470449B2/ja
Application granted granted Critical
Publication of JP7148994B2 publication Critical patent/JP7148994B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Ophthalmology & Optometry (AREA)
JP2019567981A 2017-06-12 2018-06-12 ビスホスホシンゲル製剤及びその使用 Active JP7148994B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022147051A JP7470449B2 (ja) 2017-06-12 2022-09-15 ビスホスホシンゲル製剤及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762518262P 2017-06-12 2017-06-12
US62/518,262 2017-06-12
PCT/US2018/037151 WO2018231863A1 (en) 2017-06-12 2018-06-12 Bisphosphocin gel formulations and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022147051A Division JP7470449B2 (ja) 2017-06-12 2022-09-15 ビスホスホシンゲル製剤及びその使用

Publications (3)

Publication Number Publication Date
JP2020523322A JP2020523322A (ja) 2020-08-06
JP2020523322A5 JP2020523322A5 (https=) 2021-07-26
JP7148994B2 true JP7148994B2 (ja) 2022-10-06

Family

ID=64562861

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019567981A Active JP7148994B2 (ja) 2017-06-12 2018-06-12 ビスホスホシンゲル製剤及びその使用
JP2022147051A Active JP7470449B2 (ja) 2017-06-12 2022-09-15 ビスホスホシンゲル製剤及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022147051A Active JP7470449B2 (ja) 2017-06-12 2022-09-15 ビスホスホシンゲル製剤及びその使用

Country Status (14)

Country Link
US (5) US11096954B2 (https=)
EP (2) EP3638251B1 (https=)
JP (2) JP7148994B2 (https=)
KR (3) KR20260035292A (https=)
CN (1) CN110753549A (https=)
AU (3) AU2018282905B2 (https=)
BR (2) BR112019026073B1 (https=)
CA (1) CA3066722A1 (https=)
DK (1) DK3638251T3 (https=)
ES (1) ES2981923T3 (https=)
FI (1) FI3638251T3 (https=)
MX (1) MX2019014772A (https=)
PT (1) PT3638251T (https=)
WO (1) WO2018231863A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604943C (en) 2005-04-15 2013-09-17 Clarus Therapeutics, Inc. Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
US12030908B2 (en) 2017-03-10 2024-07-09 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US11377468B2 (en) 2017-03-10 2022-07-05 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
KR102317158B1 (ko) * 2017-03-10 2021-10-25 레이크우드 아메덱스, 인크. 항미생물 화합물, 조성물, 및 그의 용도
KR20260035292A (ko) 2017-06-12 2026-03-12 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도
BR112021006954A2 (pt) * 2018-10-17 2021-07-20 Lakewood Amedex, Inc. métodos e composições para tratar mucosite oral
US11564933B2 (en) 2019-04-12 2023-01-31 Tolmar, Inc. Methods of treating testosterone deficiency
JP2024525259A (ja) * 2021-07-22 2024-07-12 レイクウッド アメデックス、インコーポレイテッド ビスホスホシンを調製するための方法
WO2025179296A1 (en) * 2024-02-22 2025-08-28 Lakewood Amedex, Inc. Crystalline forms of nu-3 and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508280A (ja) 2006-10-25 2010-03-18 オリゴス イーティーシー． インコーポレイテッド 抗微生物性および抗ウイルス性化合物ならびにそれらの使用のための方法
JP2011529098A (ja) 2008-07-28 2011-12-01 デスファルマ エジェースシェーゲージュイ ソルガールタトー コルラートルト フェレレーシュシェーギュー タルシャシャーグ 皮膚疾患／粘膜疾患の予防及び治療のための組成物、及びその使用
WO2017055295A1 (fr) 2015-09-29 2017-04-06 Galderma Research & Development Composition nettoyante auto-moussante à rincer, contenant de l'ivermectine

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4105782A (en) 1975-03-07 1978-08-08 Yu Ruey J Treatment of acne and dandruff
SE8004580L (sv) * 1980-06-19 1981-12-20 Draco Ab Farmaceutisk beredning
KR830005852A (ko) * 1980-07-18 1983-09-14 미첼 페터 잭슨 피부와 점막의 비루스 감염치료에 적합한 국소치료제의 제조방법
US4421769A (en) * 1981-09-29 1983-12-20 The Procter & Gamble Company Skin conditioning composition
DE3542516A1 (de) 1985-12-02 1987-06-04 Henkel Kgaa Desinfektionsmittel
DE3731255A1 (de) * 1987-09-17 1989-04-06 Boehringer Ingelheim Int Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
US5266310A (en) 1987-09-17 1993-11-30 Boehringer Ingelheim International Gmbh Stabilization of therapeutically active proteins in pharmaceutical preparations
US5153230A (en) 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
US5167950A (en) * 1991-03-28 1992-12-01 S. C. Johnson & Son High alcohol content aerosol antimicrobial mousse
US5208015A (en) * 1991-07-23 1993-05-04 Bristol-Myers Squibb Company Topical anti-fungal agents having anti-inflammatory activity
DE4333385C2 (de) 1993-09-30 1997-01-30 Friedrich A Spruegel Flächendesinfektions- und Reinigungsmittel
CZ267396A3 (en) * 1994-03-11 1997-03-12 Procter & Gamble HYDROLYTIC STABLE COSMETIC, PREPARATION WITH LOW pH VALUE CONTAINING ACID ACTIVE SUBSTANCES
FR2718022B1 (fr) 1994-04-01 1996-04-26 Roussel Uclaf Compositions cosmétiques ou dermatologiques et leur préparation.
FR2722102B1 (fr) * 1994-07-11 1996-08-23 Cird Galderma Utilisation de particules creuses deformables dans une composition cosmetique et/ou dermatologique, contenant des matieres grasses
US5843998A (en) 1997-06-30 1998-12-01 Song; Jin Skin blemish treatment
US6211349B1 (en) 1998-12-30 2001-04-03 Oligos Etc., Inc. Protonated/acidified nucleic acids and methods of use
US20020032164A1 (en) 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
US6627215B1 (en) 1998-12-30 2003-09-30 Oligos Etc. Inc. Devices for improved wound management
US6211162B1 (en) 1998-12-30 2001-04-03 Oligos Etc. Inc. Pulmonary delivery of protonated/acidified nucleic acids
US6156294A (en) 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media
JP2005511526A (ja) * 2001-10-18 2005-04-28 イレックス プロダクツ インコーポレイテッド ジホスホネート誘導体による皮膚の治療方法
WO2004093886A1 (en) * 2003-04-24 2004-11-04 Galderma S.A. Topical formulation of ivermectin for the treatment of dermatological conditions
CN1687100A (zh) * 2005-04-05 2005-10-26 奥林格斯技术有限公司 修饰性核苷酸及其用途
EP2419087B1 (en) 2009-04-13 2013-01-23 Sulur, Vanangamudi Subramaniam A medicinal fusidic acid cream made using sodium fusidate and incorporating a biopolymer and a process to make it
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
KR20260035292A (ko) 2017-06-12 2026-03-12 레이크우드 아메덱스, 인크. 비스포스포신 겔 제제 및 이의 용도

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010508280A (ja) 2006-10-25 2010-03-18 オリゴス イーティーシー． インコーポレイテッド 抗微生物性および抗ウイルス性化合物ならびにそれらの使用のための方法
JP2011529098A (ja) 2008-07-28 2011-12-01 デスファルマ エジェースシェーゲージュイ ソルガールタトー コルラートルト フェレレーシュシェーギュー タルシャシャーグ 皮膚疾患／粘膜疾患の予防及び治療のための組成物、及びその使用
WO2017055295A1 (fr) 2015-09-29 2017-04-06 Galderma Research & Development Composition nettoyante auto-moussante à rincer, contenant de l'ivermectine

Also Published As

Publication number Publication date
BR112019026073B1 (pt) 2021-11-03
WO2018231863A1 (en) 2018-12-20
CA3066722A1 (en) 2018-12-20
MX2019014772A (es) 2020-02-07
US11096954B2 (en) 2021-08-24
AU2018282905A1 (en) 2019-12-19
CN110753549A (zh) 2020-02-04
US20210361689A1 (en) 2021-11-25
AU2018282905B2 (en) 2022-06-02
KR20200014904A (ko) 2020-02-11
EP3638251B1 (en) 2024-03-06
EP3638251A4 (en) 2021-03-10
EP3638251A1 (en) 2020-04-22
AU2022224829A1 (en) 2022-09-29
DK3638251T3 (da) 2024-05-13
US20230125677A1 (en) 2023-04-27
JP2022183154A (ja) 2022-12-08
US12156883B2 (en) 2024-12-03
EP4241769A3 (en) 2023-11-08
KR20260035292A (ko) 2026-03-12
FI3638251T3 (fi) 2024-04-29
JP2020523322A (ja) 2020-08-06
US20250262234A1 (en) 2025-08-21
US20200360415A1 (en) 2020-11-19
KR20230031370A (ko) 2023-03-07
EP4241769A2 (en) 2023-09-13
AU2024202211B2 (en) 2025-12-04
JP7470449B2 (ja) 2024-04-18
PT3638251T (pt) 2024-05-22
BR122021011439B1 (pt) 2022-03-29
ES2981923T3 (es) 2024-10-11
NZ759577A (en) 2025-10-31
BR112019026073A2 (pt) 2020-06-30
AU2022224829B2 (en) 2024-12-05
US20180353529A1 (en) 2018-12-13
AU2024202211A1 (en) 2024-05-02

Similar Documents

Publication Publication Date Title
JP7470449B2 (ja) ビスホスホシンゲル製剤及びその使用
JP5693470B2 (ja) 銀イオンおよびメントールを含む消毒剤組成物並びにその使用
EP2496215B1 (en) Antimicrobial and anti-acne formulations
CN1946428A (zh) 具有治疗作用的抗微生物组合物和方法
US20080057136A1 (en) Disinfecting Composition and Methods of Making and Using Same
JP2008537732A (ja) ヒドロキシカルボン酸のエステルを含む抗菌組成物
WO2009054992A1 (en) Antimicrobial compositions comprising docusate
KR20040062561A (ko) 금속 이온 킬레이트제를 포함하는 항미생물성 조성물
HK40099007A (en) Bisphosphocin gel formulations and uses thereof
CN112236163B (zh) 使用协同量的硼酸增强缩酚酸肽抗生素的抗菌作用
HK40025987B (en) Bisphosphocin gel formulations and uses thereof
HK40025987A (en) Bisphosphocin gel formulations and uses thereof
CN102488701B (zh) 治疗感染的碘聚合物和莫匹罗星复方药物组合物
ZA200604768B (en) Disinfecting composition and methods of making and using same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210608

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210608

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210608

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210716

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220506

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220704

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220817

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220915

R150 Certificate of patent or registration of utility model

Ref document number: 7148994

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250